Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer | Zendy

AI Assistant Blog Pricing

Open Access

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Author(s) -

Xin Yu,

Xiangling Chu,

Yan Wu,

Juan Zhou,

Jing Zhao,

Fei Zhou,

Chaonan Han,

Chunxia Su

Publication year - 2021

Publication title -

cancer drug resistance

Language(s) - English

Resource type - Journals

ISSN - 2578-532X

DOI - 10.20517/cdr.2021.28

Subject(s) - medicine , oncology , immunotherapy , lung cancer , tumor progression , progression free survival , combination therapy , cancer , overall survival

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Download on the

Discover

Explore

Copyright Knowledge E © 2026. All Rights Reserved.